RayKnowChina Research Map
Shortlist

RecruitingCoronary heart diseasePhase not stated

Registered title, quoted from ClinicalTrials.gov

Prognosis and Antiplatelet Strategies for Patients With PCI and High Bleeding Risk:A Study Protocol

An open trial on coronary heart disease, registered on ClinicalTrials.gov. Led by West China Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorWest China Hospital四川大学华西医院ChengduHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05369442, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 1

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (1 points)Hide the checklist
  1. hemoglobin <11 g/dl, spontaneous bleeding requiring hospitalization or transfusion within the past 6 months or at any time;

    Inclusion criterion 3

    moderate chronic kidney disease [30 ml/(min*1.73m2 ) ≤ eGFR ≤ 59 ml/(min*1.73m2 )];

    Inclusion criterion 16

    11 g/dl ≤ hemoglobin < 13 g/dl in men and 11 g/dl ≤ hemoglobin < 12 g/dl in women; - spontaneous bleeding requiring hospitalization or blood transfusion in the past 6 months to 12 months;

    Inclusion criterion 17

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05369442, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

PCI patients >18 years of age and meeting 1 major criterion or 2 minor criteria of the ARC-HBR The ARC-HBR major criteria included:

  • long-term use of oral anticoagulants;
  • severe or end-stage chronic kidney disease [eGFR <30 ml/(min*1.73m2 )];
  • hemoglobin <11 g/dl, spontaneous bleeding requiring hospitalization or transfusion within the past 6 months or at any time;
  • chronic bleeding constitutional;
  • cirrhosis with portal hypertension spontaneous bleeding requiring hospitalization or transfusion within the past 6 months or at any time;
  • moderate to severe baseline thrombocytopenia (platelets <100×10\^9/L); chronic bleeding constitutional;
  • cirrhosis with portal hypertension;
  • active malignancy within the past 12 months (excluding non-melanoma skin cancer);
  • previous spontaneous brain hemorrhage (at any time);
  • traumatic brain hemorrhage within the past 12 months;
  • within the past 6 months moderate or severe ischemic stroke within the past 6 months;
  • the presence of cerebral arteriovenous malformation;
  • recent major surgery or major trauma within 30 days prior to PCI;
  • and major non-delayable surgery during DAPT.

Secondary criteria included:

  • age ≥75 years;
  • moderate chronic kidney disease [30 ml/(min*1.73m2 ) ≤ eGFR ≤ 59 ml/(min*1.73m2 )];
  • 11 g/dl ≤ hemoglobin < 13 g/dl in men and 11 g/dl ≤ hemoglobin < 12 g/dl in women; - spontaneous bleeding requiring hospitalization or blood transfusion in the past 6 months to 12 months;
  • long-term use of oral NSAIDs or steroids
  • Ischemic stroke of any duration not covered by the primary criteria.

Exclusion Criteria:

  • Patients who were already bleeding at the time of baseline inclusion
  • Patients who could not be followed up (including previously reserved phone changes, etc.) to obtain MACE events.

Quoted from ClinicalTrials.gov, NCT05369442, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05369442, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05369442